FDA approves Spravato (esketamine) nasal spray for treatment-resistant depression
The FDA approved esketamine nasal spray, marketed as Spravato, for treatment-resistant depression in adults, to be used together with an oral antidepressant. Approval came with a Risk Evaluation and Mitigation Strategy (REMS) requiring administration in a certified healthcare setting with post-dose monitoring.
This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.
Record details
- Agency
- FDA
- Jurisdiction
- United States (federal)
- Status
- Final action
- Published
- March 5, 2019
- Effective
- March 5, 2019
- Expires
- Not applicable / not verified
- Last checked
- August 24, 2026
Why it matters
This is the only ketamine-related product with FDA approval for a depression indication. Racemic ketamine used in infusion clinics remains an off-label use of an anesthetic. The REMS requirement is also why esketamine cannot be taken home.
Primary source
Drugs@FDA — SPRAVATO (esketamine) approval record, NDA 211243
Back to the Regulatory Tracker.
Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.